<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338074</url>
  </required_header>
  <id_info>
    <org_study_id>TXACOVID1</org_study_id>
    <nct_id>NCT04338074</nct_id>
  </id_info>
  <brief_title>TXA and Corona Virus 2019 (COVID19) in Outpatients</brief_title>
  <acronym>TCOutpatient</acronym>
  <official_title>Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently&#xD;
      diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and&#xD;
      virulence of the virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A recent report in Physiological Reviews proposed that the endogenous protease plasmin acts&#xD;
      on the COVID19 virus by cleaving a newly inserted furin site in the S protein portion of the&#xD;
      virus resulting in increased infectivity and virulence. Patients with hypertension, diabetes,&#xD;
      coronary artery disease, cerebrovascular illness, lung disease and kidney dysfunction&#xD;
      commonly have elevated levels of plasmin/plasminogen and it was proposed that this may be the&#xD;
      mechanism for poorer outcomes in patients with these co-morbidities. A logical treatment that&#xD;
      might blunt this process would be the inhibition of the conversion of plasminogen to plasmin.&#xD;
      There is an inexpensive, commonly used drug, tranexamic acid, (TXA), which suppresses this&#xD;
      conversion and could be re-purposed for the treatment of COVID19.&#xD;
&#xD;
      TXA is a synthetic analog of the amino acid lysine which reversibly binds four to five lysine&#xD;
      receptor sites on plasminogen. This reduces conversion of plasminogen to plasmin, and is&#xD;
      normally used to prevent fibrin degradation. TXA is FDA approved for treatment of heavy&#xD;
      menstrual bleeding (typical dose 1300 mg p.o. three times per day x 5 days) and off-label use&#xD;
      for many other indications. TXA is used perioperatively as a standard-of-care at the&#xD;
      University of Alabama at Birmingham (UAB) for orthopedic and cardiac bypass surgeries. At our&#xD;
      institution, it is commonly employed in hemorrhaging trauma patients and currently is being&#xD;
      studied for perioperative use in Cesarean section surgeries. It has also been utilized for&#xD;
      spinal surgery, neurosurgery, orthognathic surgeries and even long term for the treatment of&#xD;
      cosmetic dermatological disorders with a long track record of safety. Given the potential&#xD;
      benefit and limited toxicity of TXA it would appear warranted to perform a rapid randomized,&#xD;
      double-blind placebo controlled exploratory trial at UAB in the treatment of the early phases&#xD;
      of COVID19 to determine whether it reduces infectivity and virulence of the COVID19 virus as&#xD;
      hypothesized. Involvement of each patient is only for 7 days before primary endpoints.&#xD;
&#xD;
      An exploratory, randomized, placebo-controlled, double-blind Phase 2 clinical trial in which&#xD;
      study patients have just been diagnosed with COVID19 as an outpatient. The overall goal of&#xD;
      this exploratory study is to assess both safety and efficacy of 5 days of TXA versus placebo&#xD;
      in the COVID19 population. All patients would also receive apixaban 5 mg p.o. BID. The&#xD;
      primary endpoint for the study would be a need for hospitalization. Contact would consist of&#xD;
      daily phone contact. Care for COVID19 would otherwise be standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">April 21, 2021</completion_date>
  <primary_completion_date type="Actual">April 21, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, double-blind comparison</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Pharmacy prepares 5 day packs of medications that are coded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>Randomization to 7 days after randomization</time_frame>
    <description>Participant admission to hospital for COVID-19 treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid tablets</intervention_name>
    <description>Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos</description>
    <arm_group_label>Tranexamic Acid Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>2 tablets p.o. three times per day x 5 days</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive COVID-19 test&#xD;
&#xD;
          -  Outpatient&#xD;
&#xD;
          -  Age &gt;/= 19 y.o.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic reaction to tranexamic acid&#xD;
&#xD;
          -  History of hypercoagulation disorders (deep venous thrombosis, pulmonary&#xD;
             thromboembolism)&#xD;
&#xD;
          -  Ongoing anticoagulation&#xD;
&#xD;
          -  History of GI bleeding&#xD;
&#xD;
          -  History of Seizures&#xD;
&#xD;
          -  Cardiac or other vascular stents&#xD;
&#xD;
          -  History of severe renal disease&#xD;
&#xD;
          -  History of intracranial hemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J Ness, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <results_first_submitted>April 21, 2021</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Timothy Ness, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 3, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04338074/Prot_SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid Treatment</title>
          <description>Tranexamic acid tablets: Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos</description>
        </group>
        <group group_id="P2">
          <title>Placebo Treatment</title>
          <description>Placebo oral tablet: 2 tablets p.o. three times per day x 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid Treatment</title>
          <description>Tranexamic acid tablets: Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos</description>
        </group>
        <group group_id="B2">
          <title>Placebo Treatment</title>
          <description>Placebo oral tablet: 2 tablets p.o. three times per day x 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="32" upper_limit="45"/>
                    <measurement group_id="B2" value="37" lower_limit="34" upper_limit="40"/>
                    <measurement group_id="B3" value="38" lower_limit="32" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospitalization</title>
        <description>Participant admission to hospital for COVID-19 treatment</description>
        <time_frame>Randomization to 7 days after randomization</time_frame>
        <population>Categorical data - admitted to hospital or not</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Treatment</title>
            <description>Tranexamic acid tablets: Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>Placebo oral tablet: 2 tablets p.o. three times per day x 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization</title>
          <description>Participant admission to hospital for COVID-19 treatment</description>
          <population>Categorical data - admitted to hospital or not</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after onset of treatment</time_frame>
      <desc>There were no adverse events related to drug treatment in this truncated trial</desc>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid Treatment</title>
          <description>Tranexamic acid tablets: Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos</description>
        </group>
        <group group_id="E2">
          <title>Placebo Treatment</title>
          <description>Placebo oral tablet: 2 tablets p.o. three times per day x 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Timothy J Ness</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-975-9643</phone>
      <email>tness@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

